Surface plasmon resonance (SPR) is an optical technique that detects when molecules bind to a surface in real time, without needing fluorescent tags or radioactive labels. It works by shining light at a thin gold film and measuring how the reflected light changes as molecules interact at the surface. SPR has become a standard tool in drug discovery, biochemistry, and clinical diagnostics because it reveals not just whether two molecules bind, but how fast they come together, how fast they fall apart, and how tightly they stick.
How the Physics Works
SPR relies on a phenomenon called total internal reflection. When light travels from a dense material (like glass) into a less dense one (like water), and hits the boundary at a steep enough angle, all the light bounces back. But even during total internal reflection, a small wave of electromagnetic energy leaks past the boundary and extends a short distance into the water side. This is called an evanescent wave, and its intensity drops off sharply with distance from the surface.
Here’s where the gold comes in. A very thin gold film, typically around 50 nanometers thick, sits at that glass-water boundary. The evanescent wave penetrates through the gold and interacts with the free electrons on its surface. At one precise angle of incoming light, the evanescent wave’s energy perfectly matches the natural oscillation frequency of those surface electrons. The electrons begin to oscillate collectively, forming what physicists call a surface plasmon. At this “resonance” angle, energy transfers from the light into the electron oscillation, and the intensity of reflected light drops sharply. That dip in reflected light is the SPR signal.
The critical detail: the exact angle where resonance occurs depends on the refractive index of whatever is sitting on the gold surface. When a protein binds to a molecule tethered to the gold, it changes the local refractive index, which shifts the resonance angle. By tracking that angular shift over time, researchers watch binding happen in real time.
What’s Inside an SPR Instrument
A typical SPR biosensor uses the Kretschmann configuration, which sounds complicated but is conceptually simple. A glass prism sits on top of a sensor chip, which is a glass slide coated with a thin layer of gold. A light source, often a quartz tungsten-halogen lamp, sends polarized, single-wavelength light through the prism and onto the gold film. On the other side of the gold, a flow channel carries liquid samples (buffer, proteins, drug candidates) across the surface. A detector on the reflection side continuously monitors the angle and intensity of the reflected light.
The gold surface isn’t bare. It’s coated with a thin layer of a sugar-based polymer called carboxymethyl dextran, which provides anchor points for attaching “probe” molecules. These probes are whatever the researcher wants to study: antibodies, enzymes, peptides, or DNA strands. The attachment chemistry typically uses a reaction called amine coupling, where a chemical activation step creates reactive groups on the polymer that form covalent bonds with the probe molecule. This locks the probe firmly in place so the sensor can be used repeatedly.
Reading a Sensorgram
The primary output of an SPR experiment is a sensorgram, a graph that plots the SPR signal (in response units) against time. A typical experiment has three phases, and each one tells you something different.
First comes association. A solution containing the molecule of interest (called the analyte) flows over the surface. As analyte molecules bind to the immobilized probes, the refractive index near the surface increases and the signal rises. The curve during this phase follows an exponential shape, climbing steeply at first, then leveling off as binding sites fill up.
Next is steady state. If the analyte flows long enough, binding and unbinding reach equilibrium and the signal plateaus. This plateau height relates to how much analyte is bound at any given moment.
Finally, dissociation. The analyte solution is replaced with plain buffer. Now molecules can only fall off the surface, not rebind, so the signal decays. The steepness of this decay tells you how quickly the interaction falls apart.
What SPR Actually Measures
From the shape of the sensorgram, researchers extract three key numbers. The association rate constant (ka) describes how quickly two molecules find each other and bind. The dissociation rate constant (kd) describes how quickly they let go. Dividing kd by ka gives the equilibrium dissociation constant, KD, which is the single most important number in binding studies. A smaller KD means tighter binding. A drug candidate with a KD in the low nanomolar range, for example, binds its target very strongly.
This trio of values is far more informative than just knowing whether two molecules interact. Two drug candidates might bind a target with the same overall affinity, but one grabs on quickly and lets go quickly, while the other binds slowly but hangs on for a long time. Those kinetic differences can dramatically affect how a drug works in the body, and SPR is one of the few techniques that distinguishes between these scenarios directly.
Why Label-Free Detection Matters
The traditional workhorse for detecting molecular interactions in biology is the ELISA (enzyme-linked immunosorbent assay). ELISA requires a secondary antibody carrying a fluorescent dye or enzyme label to visualize whether binding occurred. That label can sometimes interfere with the interaction being measured, and the assay only gives you an endpoint, a single snapshot of how much binding happened after a fixed incubation period.
SPR detects binding through changes in refractive index at the surface, so no labels are needed. This eliminates the risk of labels distorting results and means you can watch the entire binding process unfold. You see association, equilibrium, and dissociation all in one experiment. SPR also uses less protein than many competing methods, which matters when studying targets that are expensive or difficult to produce.
Applications in Drug Discovery and Medicine
SPR’s biggest commercial role is in drug discovery. Pharmaceutical companies use it to screen libraries of small chemical fragments against disease-relevant protein targets. Fragment-based drug discovery starts with tiny molecules (smaller than typical drugs) and builds them up into potent compounds. SPR is well suited for this because it can detect the weak binding of fragments that other methods miss, with reported affinities ranging from sub-micromolar to low micromolar. Screening campaigns have targeted enzymes implicated in Alzheimer’s disease, blood clotting, and cancer, among others. Running SPR screens before turning to more expensive techniques like X-ray crystallography saves time and narrows the field of candidates.
In biomedical research, SPR biosensors are being developed to detect disease biomarkers directly in blood serum and other clinical samples. Modern instruments can detect analytes at extraordinarily low concentrations. Published studies report limits of detection as low as fractions of a femtogram per milliliter for certain targets, with refractive index resolution on the order of 10-6 refractive index units. Specific examples include detecting prostate-specific antigen (PSA) at 9 picograms per milliliter in serum, beta-amyloid peptides associated with Alzheimer’s disease at roughly 0.001 picograms per milliliter in animal blood, and cancer-associated microRNA in urine at 0.0003 picomolar concentrations.
Practical Challenges
SPR is powerful, but it’s not without complications. One common issue is the bulk refractive index shift. When a new solution flows across the sensor, the buffer itself may have a slightly different refractive index than the running buffer, causing a jump in signal that has nothing to do with binding. Researchers handle this by running a reference channel, a second flow cell with no immobilized probe, and subtracting its signal from the active channel. More sophisticated correction methods use the total internal reflection angle itself to calculate and remove the bulk contribution.
Surface regeneration is another practical consideration. After each binding cycle, the surface needs to be stripped of bound analyte so it can be reused. This typically involves a brief wash with an acidic or basic solution that disrupts the interaction without damaging the immobilized probe. Finding the right regeneration conditions can take trial and error, and harsh regeneration can gradually degrade the surface over many cycles.
Finally, SPR measures everything that accumulates on the surface, not just the target molecule. In complex samples like blood serum, nonspecific sticking of unwanted proteins can obscure the real signal. Careful surface chemistry and blocking steps are essential for getting clean data from biological fluids.
Localized SPR With Nanoparticles
A related technique called localized surface plasmon resonance (LSPR) uses metallic nanoparticles instead of a flat gold film. When light hits a gold or silver nanoparticle, the electrons oscillate collectively but are confined to the tiny particle rather than propagating along a flat surface. This confinement creates an intense, highly localized electromagnetic field around the nanoparticle. Changes in the local environment, such as a molecule binding to the nanoparticle surface, shift the wavelength of light the particle absorbs most strongly.
LSPR sensors can be simpler and cheaper than prism-based SPR instruments because they don’t require the precision optics of the Kretschmann setup. They’re especially promising for point-of-care diagnostics. In one example, an LSPR-based sensor detected thyroglobulin, a thyroid cancer biomarker, in serum at a limit of detection below 0.1 femtograms per milliliter, among the most sensitive results reported for any SPR-based platform.